RESUMO
Additional phase III multicenter clinical study was performed to investigate the efficacy, safety, and usefulness of somatostatin receptor scintigraphy using 111In-pentetreotide (MP-1727), which binds to somatostatin receptors. Forty patients were included in the study; Group A: 18 patients, gastrointestinal hormone producing tumors had been detected with conventional imaging modalities, Group B: 22 patients, no tumors had been detected with conventional imaging modalities in spite of high serum hormone levels. By comparing the results of the octreotide suppression test, 12/16 cases (75.0%) of Group A and 11/19 cases (57.9%) of Group B were assessed as "effective." By comparing the results of immunohistological examination, 5/9 cases (55.6%) of Group A and 2/4 cases (50.0%) of Group B were assessed as "effective." Severe adverse events were not observed in any of the evaluable 35 cases. MP-1727 was judged as clinically useful in 11/16 cases (68.8%) of Group A and 5/19 cases (26.3%) of group B. These results suggest that MP-1727 scintigraphy is very useful for the diagnosis and decision of the therapeutic strategy of gastrointestinal hormone producing tumors.
Assuntos
Hormônios Gastrointestinais/biossíntese , Radioisótopos de Índio , Neoplasias/diagnóstico por imagem , Compostos Radiofarmacêuticos , Receptores de Somatostatina/metabolismo , Somatostatina/análogos & derivados , Idoso , Feminino , Humanos , Radioisótopos de Índio/metabolismo , Masculino , Pessoa de Meia-Idade , Neoplasias/metabolismo , Cintilografia , Compostos Radiofarmacêuticos/metabolismo , Somatostatina/metabolismoRESUMO
The pancreatic endocrine tumors are uncommon neoplasms and are classified into non-functional and functional tumors. According to whether the secreted hormones are originated from pancreatic islet cells or not, the tumors are also classified into normotopic and ectopic tumors. Except for insulinoma, more than 60% of them reveal malignant behavior. The presence of endocrine tumor is diagnosed when patients develop a hormone-specific symptom, and the location of tumors are usually diagnosed by a combination of ultrasonography, computed tomography, magnetic resonance imaging and selective angiography. A somatostatin receptor scintigraphy is promising. Nevertheless, these examinations occasionally failed to precisely locate the tumors especially when they are very small and/or multiple. For such cases, both portal venous sampling and arterial provocation test are helpful.